

REGEN-D[®] 150

Recombinant Human Epidermal Growth Factor gel


BHARAT
BIOTECH
Lead Innovation

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

1. NAME OF THE MEDICINAL PRODUCT

Name of the product: Recombinant Human Epidermal Growth Factor gel

Strength: Each gram of gel contains

Purified Bulk of rh - Epidermal Growth Factor: 150µg

Pharmaceutical Form: Gel

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gram of gel contains

Ingredients	Quantity / g
Purified Bulk of rh - Epidermal Growth Factor:	150µg
Sodium Methylparaben IP	1.8mg
Sodium Propylparaben IP	0.2mg
Excipients	q.s

3. PHARMACEUTICAL FORM

Gel.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications:

REGEN-D[®]150 is indicated for healing diabetes mellitus associated foot ulcers, bedsores (pressure ulcers), chronic leg ulcers (venous ulcers).

4.2 Posology and Method of Administration

Cleanse the ulcer wound and surrounding surface with water or saline and pat dry with sterile cotton before the gel is applied. Apply the gel evenly (topical application) on the affected area of the skin using sterile cotton swab twice a day till the ulcer area heals. **REGEN-D[®] 150** therapy should be continued up to a period of 2 to 3 weeks after the wound heals. The continuation of the therapy is at the discretion of the physician.

a) A single tube should be used for individual patient.

b) Avoid direct contact of the tube with the wound area

Any unwarranted use of the product is not the responsibility of the manufacturer.

4.3 Contraindications

REGEN-D[®] 150 is generally well tolerated. However, the product should not be applied or repeated to persons known to be hypersensitive to any of the components of the product. Also, it should not be applied to individuals who are receiving immunosuppressive or immunostimulant therapy, or in immune compromised individuals.

4.4 Special Warnings and Precautions for use

It is suggested that the medical practitioner ascertain the hypersensitivity status of the subject.

4.5 Interactions with Other Medicinal Products and other forms of interaction

REGEN-D[®] 150 must not be used with other growth factor containing gel or cream.

4.6 Pregnancy and Lactation

REGEN-D[®] 150 is contraindicated for use in pregnant and lactating woman.

4.7 Effects on Ability to Drive and Use Machines

Since the product is topical application, systemic absorption is not expected. However, no studies on the effect of **REGEN-D[®] 150** on the ability to drive and use machines has been performed.

4.8 Undesirable Effects

REGEN-D[®] 150 has proven low reactogenicity and is well tolerated, however, skin irritation/pain rash at the application site may be seen in very few cases.

4.9 Over-dose

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

EGF is part of a complex network of growth factors and receptors that together help to modulate the growth of cells. EGF is released by cells, and then is picked up either by the cell itself, stimulating its own growth, or by neighboring cells, stimulating their ability to divide. Receptors on the surface of the cell bind to EGF and relay the signal inside. When the receptor binds to EGF, it is activated by forming a dimer with other receptors.

EGF is essential for mediating the de-differentiation of keratinocytes to an epithelial lineage and to reestablish the epithelial barrier. EGF binds to the EGFR, a protein tyrosine kinase receptor, expressed on the majority of cells in the skin. Activation of EGFR leads to a number of biological responses, including migration, proliferation, cytoprotection, cellular differentiation, and apoptosis. In wound healing EGFR plays an important role in re-epithelialization and dermal maturation. Topical use of recombinant human EGF has been shown to increase re-epithelialization and enhance wound healing.

5.2 Pharmacokinetic Properties

Subjects were followed up for various periods of time to evaluate the systemic absorption of **REGEN-D[®] 150** in blood. Sera was analyzed for anti-EGF titers by Indirect ELISA method.

The test serum absorbance was less than the seroconversion cut-off value, hence these samples were negative for anti r-human EGF antibody.

Patients with wounds were tested for the presence of rhEGF by collecting the samples from the site of application, the result clearly shows that rhEGF is available at the site of application. Protease enzyme present in the body degrades rhEGF at the site of applications, however when **REGEN-D[®]150** was applied, there was sufficient high concentration of rhEGF locally.

5.3 Preclinical safety data

Pre-clinical toxicological studies done on rats and rabbits concluded that the rh-EGF is safe and well tolerable with no systemic observations. The study was conducted to evaluate the potential toxicity of repeated doses (75-300 µg/Kg) of recombinant human Epidermal Growth Factor applied topically to rats and New Zealand white rabbits. groups. The rh-EGF was not absorbed systematically as revealed in the systemic absorption study conducted in rabbit. There has been significant increase in the DNA and collagen contents in the skin samples treated with rh-EGF. No significant changes were observed control and treated groups with respect to protein contents in the skin.

In another study with rats (Wistarfurth) and rabbits (New Zealand white) to evaluate the potential toxicity of repeated doses (75-300 µg/Kg) of rh-EGF applied topically to rats and rabbits, it was found that there was no observable antibody response in the treated groups with EGF in both rats and rabbits. The DNA content in skin sample of treated group has significantly increased in high dose in both the species on 15th and 31st day. The protein content in the control and treated groups did not differ significantly in both the species studied. The collagen content was significantly increased in medium and high dose groups in males and females both the species on 15th and 31st days.

In a multi-centre, double-blind, randomised, parallel, placebo-controlled phase 3 study to evaluate the safety and efficacy of **REGEN-D[®] 150** as a treatment for diabetic foot ulcers, there was a reduction of healing time to an average of 9 weeks compared to the controls within the cut off observation period of 15 weeks. When compared at 15 weeks, 86% healed whereas only 50% healed in the placebo group.

A study conducted in Wistar NIN rats to study the effect(s) of rhEGF on naproxen-induced gastric ulcer, showed that treatment with 100 µg/kg rhEGF significantly resulted in healing of ulcers by 14 days. There was a significant increase in immunoreactivity for Cox-2 was observed, when compared to control group.

A multi-centre, randomised, double-blind phase 3, placebo-controlled study was conducted to evaluate the safety and efficacy of recombinant human epidermal growth factor (**REGEN-D[®] 150**) in patients with bed sores (pressure ulcers). Topical application of **REGEN-D[®] 150** gel applied twice daily for 12 weeks was found to be safe and efficacious as it significantly accelerates the rate and number of healing compared to placebo in subjects with bed sores

(pressure ulcer). On an average, it took about 40 days to heal bed sores, in contrast it took about 78 days to heal with placebo. There was one case of rash in in EGF group and two cases of irritation in placebo group. Both these conditions resolved within 48 hours and the subjects continued in the study. These adverse reactions are similar to that reported in previous studies. There were no serious adverse reactions reported. None of the enrolled subjects were withdrawn from study for drug related adverse reaction.

A phase 3 multicenter double-blind, randomized (1:1), parallel study was conducted at 3 centers to evaluate the efficacy and safety of **REGEN-D[®] 150** gel applied topically in patients with Grade I or II (Wagner's classification) diabetic foot ulcers and to compare the time required for complete healing of the ulcer in the test group and control group. Healing occurred in about 13 weeks for placebo-treated ulcers and 9 weeks for the rhEGF gel-treated ulcers. The percent of completely healed ulcers in the gel-treated population in week 5, week 10, and week 15 was roughly 18%, 66%, and 84%, respectively. Studies on EGF in diabetic foot ulcers have documented similar results. EGF was found to be a practical treatment solution for diabetic foot ulcers. Treatment with **REGEN-D[®] 150** was not cumbersome and does not involve complicated dressing procedures.

In a study conducted by Rajesh Kesavan et al, **REGEN-D[®] 150** was compared with placebo in patients with uninfected diabetic foot ulcers. The study showed that **REGEN-D[®] 150** increased collagen content of the wound by 3.6-fold, whereas it was 2.6-fold increase in the placebo group. Collagen type 1 expression was more in **REGEN-D[®] 150** than in placebo group. The MMP-9 expression was more in the **REGEN-D[®] 150** on the 15th day, where it was on the 30th day in the placebo group. The study established the safety and efficacy of **REGEN-D[®] 150** in healing of DFU.

Post-marketing Experience

Post-marketing surveillance (PMS) study of **REGEN-D[®] 150** in 135 patients with diabetic foot ulcer in India was compared with phase 3 clinical trial data of **REGEN-D[®] 150** in India. Statistical analysis of study data determined that the empirical survival probability distribution, in terms of non-healing of ulcers, was lowest in the case of PMS study, better than that for phase 3; more DFU patients were healed in PMS study. Percentage of patients cured in any given week (e.g., in week 10) is above 90% in PMS study, as compared to 69% in phase 3 clinical trial; this percentage was around 18% for the placebo-control group in the phase 3 trial. The average wound healing time was significantly lower in PMS study, 4.8 weeks, while it was 9 weeks in Phase III clinical trials while the average wound healing with **REGEN-D[®] 150** was found to be 86% in this study. **REGEN-D[®] 150** has been found to result in healthy granulation and stimulate epithelization, thus leading to final wound closure. The PMS study has established the efficacy of **REGEN-D[®] 150** in faster healing of chronic non-healing diabetic foot ulcers.

A phase 4, post-marketing surveillance study of **REGEN-D[®] 150** was undertaken to study the efficacy of rhEGF in diabetic foot ulcers. Parameters evaluated included ulcer outcome; percentage of healing; duration of healing; and quality of healing and epithelization. All patients (n = 54) who were enrolled for the study resulted in good clinical outcome, i.e., ulcers had significantly improved in terms of both percentage of wound closure and quality of healing (Table 6). The average time required for the healing of an ulcer in this cohort was around 5.5 weeks. An average of 83% wound closure in the cohort was documented. Moreover, the quality and epithelization were excellent.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Sodium Methylparaben IP

Sodium Propylparaben IP

6.2 Incompatibilities

Recombinant human EGF is combined along with silver sulfadiazine and chlorhexidine, marketed as **SLVRGEN[®]** is manufactured by Bharat Biotech and is used for the treatment of first and second-degree burns and ulcers like abrasions, incisions, minor cuts and wounds. No other studies were performed to look for incompatibilities with **REGEN-D[®] 150**.

6.3 Shelf Life

The expiry date of the product is indicated on the carton.

6.4 Special precautions for Storage

Store in a Room Temperature (25°C ± 2°C). Do not freeze. Do not use after the expiry date.

6.5 Nature and contents of container

REGEN-D[®] 150 is presented in aluminum tube with polypropylene screw cap.

The pack sizes are: 7.5gm, 15gm, 30gm, 50 gm and 150gm.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

REGEN-D[®] 150

Recombinant Human Epidermal Growth Factor gel



7. MARKETING AUTHORISATION HOLDER



Bharat Biotech International Limited situated
Sy. No. 230, 231 & 235, Genome Valley,
Turkapally, Shamirpet Mandal,
Medchal, Malkajgiri District, Telangana State, India, Pin: 500078.

8. MARKETING AUTHORISATION NUMBER

MF-4077/05

9. DATE OF FIRST MARKETING AUTHORISATION

12 May 2005

10. DATE OF REVISION

Last revision date: September 2019

59PTD.02
1400001883